Answers are grounded in this paper and cite their sources.
This randomized controlled trial finds that tocilizumab affects endothelial function in comatose cardiac arrest patients, suggesting complex inflammation links.
Plasma syndecan-1 decline was less pronounced in comatose OHCA patients treated with tocilizumab, without affecting sTM or PECAM-1. This contrasts previous IMICA findings of reduced systemic inflammation, vasopressor use, and myocardial injury, suggesting a complex relationship between inflammation and endothelial injury.Finally, PECAM-1 levels already at hospital admission had a moderate predictive value for mortality.
No takes yet. Share an insight, caveat, or question.
Alaoui-Ismaili et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: